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Background: It has been postulated that non-steroidal anti-inflammatory drugs (NSAIDs) use leads to decreased
prostate cancer (PCa) risk. In recent years, NSAIDs’ role in PCa development has been extensively studied; however,
there is not yet a definitive answer. Moreover, the epidemiological results for NSAIDs’ effect on PCa-specific
mortality have been inconsistent. Therefore, we performed a meta-analysis to examine the controversy.
Methods: We performed a literature database search and included all published studies conducted in the general
population exposed to any NSAID, extracting an odds ratio (OR) or a hazard ratio (HR) with 95% confidence
intervals (95% CIs) that compared the incidence of PCa or PCa-specific mortality with non-exposure. We derived a
pooled OR or HR using random or fixed effects models, as appropriate. Subgroup analyses were also performed.
Results: Thirty-nine studies (20 case–control and 19 cohort studies) were included in this analysis. Thirty-one studies
were available concerning NSAID use and PCa incidence and eight studies on PCa-specific mortality. Compared to
non-use, aspirin use was statistically significantly associated with PCa incidence risk, and the association was slightly
stronger for advanced PCa than for total PCa (OR = 0.92, 95% CI = 0.87 to 0.97 for total PCa; OR = 0.81, 95%
CI = 0.73 to 0.89 for advanced PCa). Aspirin use seems also to be associated with a modest reduction in PCa-specific
mortality (HR = 0.86, 95% CI = 0.78 to 0.96 for total PCa; OR = 0.81, 95% CI = 0.71 to 0.92 for advanced PCa). Generally,
the pooled effects for any NSAIDs, NA-NSAIDs and cyclooxygenase-2 inhibitors demonstrated no adverse or beneficial
effects on PCa development or PCa-specific mortality, but the results were not consistent. The effect estimates did not
vary markedly when stratified by study design and study quality but varied by geographic region. Furthermore, long-term
aspirin use (≥4 years) was also significantly associated with reduced PCa incidence (OR = 0.88, 95% CI 0.79 to 0.99).
Conclusions: The present meta-analysis provides support for the hypothesis that aspirin use is inversely related to PCa
incidence and PCa-specific mortality. The effect estimates, varying by geographic region, deserve further investigation.
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Prostate cancer (PCa) is one of the most frequently oc-
curring cancers and cause of cancer-related deaths in
men [1]. According to the latest report from the American
Cancer Society, in 2014, 233,000 new cases will be diag-
nosed, and 29,480 estimated deaths from PCa are predicted* Correspondence: qinxue919@126.com
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unless otherwise stated.in the United States [1]. Although the five-year relative
survival rate has increased over the past 25 years [2], PCa is
still the leading cause of cancer death in older men [1].
There is an urgent need for a better understanding of the
factors related to PCa development and prognosis.
Cyclooxygenase-2 (COX-2), an inducible enzyme, is
overexpressed in PCa tissue [3] and plays a role in PCa
cell growth [4]. Aberrant or high expression of COX-2 has
been implicated in carcinogenesis and poorer prognosis
[5,6]. Therefore, it has been speculated that non-steroidalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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COX pathway, may provide a strategy for mechanistically
based PCa chemoprevention and therapy [3]. Indeed, a
number of epidemiologic studies have investigated the
association between NSAID use and the risk of PCa but
showed conflicting results, with the majority finding null
effects [7-22], some reporting statistically significant inverse
associations [23-34] and a minority reporting a significantly
elevated risk of prostate cancer in association with NSAID
or non-aspirin NSAID (NA-NSAID) use [35-37]. In a study
conducted by Mahmud et al. [38], which searched data-
bases in June 2008, the association of the use of aspirin
and other NSAIDs with PCa incidence was suggestive
but not conclusive. Several observational studies published
after this meta-analysis have shown contrasting results
[19-22,32-34,36,37], which has added new evidence to the
previous research. On the other hand, since considerable
evidence implies that aspirin use may reduce the risk of
PCa, a better understanding of whether such therapy can
influence disease outcome is important and necessary. To
date, several studies have examined NSAID (aspirin) use
and PCa-specific mortality, and these have reported
conflicting findings [39-46].
Given widespread and long-term NSAID use, more
knowledge is needed to clarify the drugs’ role in PCa in-
cidence and mortality. Therefore, we performed a com-
prehensive review and provide a quantitative assessment
of all relevant published studies to understand this issue
better. A better understanding of the relationship may also
highlight the importance of considering additional preven-
tion methods in this area.
Methods
Data sources and searches
This study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist [see Additional file 1] [47]. Three
authors (YL, JC and LX) experienced in Cochrane review
searched electronic databases for articles published through
29 December 2013. The databases included PubMed,
Embase, ISI Web of Science and the WHO Library
Database. The search terms included the therapeutic clas-
ses, generic names of individual drugs and PCa outcome
terms [see Additional file 2]. No language restrictions were
imposed. Additional studies were searched for manually
through the reference lists of retrieved articles and using
PubMed’s related articles option.
Eligibility criteria and study selection
To be included, studies had to meet the following criteria:
(1) studied participants were exposed to any NSAID,
including aspirin, NA-NSAIDs, any other single NSAID
(not including acetaminophen) or a mixture of NSAIDs or
selective COX-2 inhibitors and reference participants hadnot used these drugs; (2) the study assessed the incidence
of PCa or PCa-specific mortality; and (3) the study reported
the multivariate-adjusted relative risks (RRs), including
study-specific odds ratios (ORs) or hazard ratios (HRs) and
95% confidence intervals (CIs). No study design restrictions
were imposed. Reviews, letters, comments, lectures and
case reports were all excluded. When study populations
overlapped, only the study of larger size or the most in-
formative one was included. However, if overlapping studies
offered additional information for subgroup analysis that
could not be extracted from the primary studies, they were
included in the subgroup analysis. Two authors (JW, TL)
independently evaluated all records by title and abstract
and subsequently retrieved and assessed in detail the
full text of any potentially relevant articles according
to the eligibility criteria. Disagreements or uncertainties
regarding eligibility were resolved through discussion with
two additional adjudicators (XQ, SL).
Data extraction and quality assessment
For each trial, the study and participant characteristics,
number of cases and controls, drug types, exposure period
and multivariable adjusted RR estimates with correspond-
ing 95% CIs were extracted and transferred to specially
designed forms. If the required data for the meta-analysis
were not readily available in the published article, the
principal author was contacted at least once. Data were
obtained and independently reviewed by two reviewers
(YL and SL), and the final decision was reached by consen-
sus. The methodological quality of observational studies was
assessed by two authors (XQ and YL) independently using
the Newcastle-Ottawa scale (NOS) [48]. Disagreement
was resolved by consensus. In this scale, studies are
awarded a maximum score of 9 points; a high-quality study
is awarded ≥7 points, a medium-quality study between 4
and 6 points and a poor-quality study <4 points.
Data synthesis and statistical analysis
We evaluated the association of NSAID use with two
endpoints: (1) the OR of PCa incidence and (2) the HRs
of PCa-specific mortality. Pooled ORs and HRs with
95% CI were obtained using a fixed effects model [49] or
the random effects model of DerSimonian and Laird [50]
if needed due to between-study heterogeneity. Because the
evaluated outcomes are relatively rare and the effects
estimated are generally small, ORs in case–control studies
were considered reasonable approximations of the corre-
sponding risk ratios in cohort studies [51], permitting
the combination of cohort and case–control studies.
Inter-study heterogeneity was tested by Cochran’s Q
test [52] and quantified by the I2 statistics [53]. For the
Q statistic, a P value <0.10 was considered statistically
significant for heterogeneity; for I2, a value >50% indicates
a measure of heterogeneity [52]. Cumulative meta-analysis
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over time. We assessed publication bias graphically using
a funnel plot and quantitatively using the Begg rank
correlation test and the Egger regression asymmetry
test [54,55] where numbers of studies allowed (>10 studies).
Sensitivity analyses were also conducted to assess the
robustness of the results by the sequential omission of
individual studies [56].
To detect potential interactions, studies were stratified by
the type of medicine (NSAIDs overall, aspirin, NA-NSAIDs
and COX-2 inhibitors) and study outcome (total PCa
(all cancers regardless of stage), advanced cancers (lesions
with extracapsular extension or metastases to regional
lymph nodes or other organs) and non-advanced cancers).
Further subgroup analysis estimated the effects of NSAIDs
on PCa risk by study design, studies defined as high quality,
geographic region and duration of aspirin use. A two-tailed
P value <0.05 was considered statistically significant.
All analyses were performed using STATA version 12.0
(StataCorp, College Station, TX, USA).
Results
Study selection, characteristics and quality
Our initial search identified 4,331 studies, of which we
obtained 51 full-text articles, and 39 studies [7-37,39-46]
were included in the review. References for studies ex-
cluded from the full-text study review process and the
additional records identified through a manual review
are listed in Additional file 3. A PRISMA trial flow diagram
for systematic review is presented in Figure 1. One article
from the Cancer Prevention Study II Nutrition Cohort by
Jacobs et al. [18] in 2007 was excluded from the primary
outcome analysis because this article only updated the
duration-effect of aspirin contrasting the primary group
[14]; therefore, the study data were re-entered for sub-
group analyses for duration of aspirin.
The studies that met the inclusion criteria were all
observational studies, comprising 20 case–control
[9-11,16,17,21-23,26,28-33,35-37,41,44] and 19 cohort
studies [7,8,12-15,18-20,24,25,27,34,39,40,42,43,45,46]
involving more than 924,502 male subjects, includ-
ing 108,136 PCa cases. Thirty-one studies (18 case–
control [9-11,16,17,21-23,26,28-33,35-37] and 13 cohort
[7,8,12-15,18-20,24,25,27,34]) addressed the use of any
NSAID and its association with PCa incidence risk
(Table 1); eight studies (two case–control [41,44] and six
cohort [39,40,42,43,45,46]) investigated whether NSAID
use was associated with PCa-specific mortality (Table 2).
For NSAID use and PCa incidence risk, the publication
dates of the studies ranged between 1989 and 2014. A
majority of the studies were conducted in North America
(16 in the USA and four in Canada) and 10 in Europe.
For NSAID use and PCa-specific mortality, five studies
[39-41,43,45] measured exposure to aspirin, one study [44]addressed any NSAIDs, one study [46] covered only NA-
NSAIDs, and one study [42] employed all three categories.
With regard to the quality of all the included studies
assessed by NOS (Table 1 and Table 2), 18 studies (46.2%)
were graded as having good quality (seven or more points),
20 (51.3%) were graded as medium-quality (four to six
points), and one study (2.5%) conducted in 1989 was
graded as poor-quality (three points). The details of the
quality assessment are presented in Additional file 4.
Association between the use of any NSAID and the
incidence of prostate cancer
Eleven studies (eight case-controls and three cohorts)
evaluated exposure to any NSAIDs and the incidence of
total PCa, and five studies examined the effect of any
NSAIDs on the incidence of advanced PCa, but no studies
examined non-advanced PCa. Figure 2 shows the study-
specific and pooled ORs and 95% CIs of PCa for any
NSAID users versus non-NSAID users. The summary OR
for the 11 studies that assessed the effect of any NSAIDs
on total PCa was 0.90 (95% CI: 0.75 to 1.07; I2 = 93.5%). The
effect estimates were similar for five studies on any NSAIDs
and advanced PCa (OR = 0.86, 95% CI: 0.52 to 1.40)
(Figure 2, Table 3). These analyses yielded substantial
heterogeneity (I2 = 93.5% and I2 = 94.2%, respectively)
and revealed that any NSAIDs were not associated with a
significant decrease in the incidence of PCa.
In sensitivity analyses, none of the individual studies
substantially altered the pooled ORs for any NSAIDs on
total PCa, which varied from 0.86 (95% CI, 0.71 to 1.04)
to 0.96 (95% CI, 0.81 to 1.14). The direction and magnitude
of the negative effect did not vary markedly when stratified
by study design (Table 3). However, when we combined
studies by geographic region, the six studies from North
America had a summary OR of 0.73 (95% CI: 0.60 to 0.88;
POR =0.001; I
2 = 79.6%), whereas the other five studies from
Europe had a higher and statistically significant summary
OR of 1.29 (95% CI: 1.25 to 1.34; POR <0.001; I
2 = 37.2%)
(Table 3).
For publication bias assessment, the inverted funnel plot
was potentially asymmetric, and the results of the Begg test
(P = 0.350) and the Egger test (P = 0.037) implied some evi-
dence of publication bias (Figure 3A).
Association between aspirin use and PCa incidence
Twenty-three studies, thirteen studies, and six studies
evaluated exposure to aspirin and the incidence of total
PCa, advanced PCa, and non-advanced PCa, respectively.
Figure 4 graphs the ORs and 95% CIs from the individual
studies and the pooled results. The 23 studies that assessed
the effect of aspirin on total PCa showed an inverse as-
sociation (OR = 0.92, 95% CI: 0.87 to 0.97) and were
moderately heterogeneous (I2 = 66.2%, P<0.001). The 13
studies of advanced PCa were consistent; the risk decrease
Figure 1 Flow of selection for studies through review.
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(OR = 0.81, 95% CI: 0.73 to 0.89; I2 = 23.9%). However, a
non-significant decreased risk was observed in non-
advanced PCa (OR = 0.96, 95% CI: 0.87 to 1.07), with little
evidence of heterogeneity (I2 = 34.6%, P = 0.177).
We saw no evidence of obvious influential studies in
sensitivity analyses by the sequential omission of individual
studies. The summary ORs for total cancer were reasonably
stable, ranging from 0.91 when the study by Friis et al. [12]
was excluded to 0.94 when the study by Rodriguez et al.
[27] was excluded. Table 3 shows the results of the sub-
group analyses. The risk decrease persisted for both
total and advanced PCa when the data were stratified
into subgroups based on study design and study quality.
The effect sizes showed moderate statistical heterogeneity
among studies of total PCa but no heterogeneity among
studies of advanced PCa. Adjustment for geographic
region had the strongest influence on the summary
OR, demonstrating negative results.
We examined the association between long-term aspirin
use (defined as ever use of aspirin for more than four years)
and risk of total PCa incidence using the data available
from the included studies. Eight studies [15,17-20,26,27,32]
were included in this analysis. The pooled results slightly
strengthened the association of aspirin use with total PCa
(OR: 0.88, 95% CI: 0.79, 0.99) (see Table 3 and Additional
file 5: Figure S1). Most studies lacked information on thedose and frequency of aspirin use, or the information varied
in each trial; hence, a statistical analysis of significance be-
tween these groups was not valid.
A visual inspection of the funnel plot found no evidence
of publication bias (Figure 3B). The P values for the Begg
test and the Egger test were P = 0.316 and P = 0.273,
respectively, both suggesting a very low probability of
publication bias.
A cumulative meta-analysis of a total of 23 studies of
total PCa was carried out to evaluate the cumulative effect
estimate over time. In 1989, Paganini-Hill et al. [7] first re-
ported a non-significant effect estimate of 0.95. Between
1994 and 2006, 14 studies were published, with a cumula-
tive OR of 0.89 (95% CI: 0.81 to 0.98). A statistically signifi-
cant effect of aspirin use on PCa incidence was consistently
observed after publication of the 13th trial in 2006. Between
2007 and 2013, eight more publications were added cu-
mulatively, resulting in an overall effect estimate of 0.92
(95% CI 0.87 to 0.97) [see Additional file 5: Figure S2].
Association between NA-NSAID use and PCa incidence
Seventeen studies, nine studies, and three studies evaluated
exposure to NA-NSAID and the incidence of total PCa, ad-
vanced PCa, and non-advanced PCa, respectively. Figure 5
illustrates the ORs and 95% CIs from the individual studies
and the pooled results. The meta-analysis revealed that
NA-NSAID use was not significantly associated with
















Veitonmaki, 2013 [37] Finland 24,657 24,657 68 1995–2002 ASA/NSAIDs/ NA-NSAIDs/
COX-2 inhibitors
Total/advanced PCa Database 1–5 8
Kopp, 2013 [22] Denmark 334 334 59.0 1993–1997 NSAIDs Total PCa Questionnaire 1, 6, 7 4
Vinogradova, 2011 [21] UK 14,764 192,081 69 1997–2008 COX-2 inhibitors Total PCa Database 1, 8–11 7
Murad, 2011 [36] UK 1,016 5,043 63 2001–2008 ASA/NSAIDs/ NA-NSAIDs Total PCa Questionnaire 1, 12–15 6
Mahmud, 2011 [33] Canada 9,007 36,028 73 1985–2000 ASA/NSAIDs/ NA-NSAIDs Total PCa Database 1, 14–17 6
Salinas, 2010 [32] USA 1,001 942 63 2002–2005 ASA/ NA-NSAIDs/
COX-2 inhibitors
Total/advanced PCa Questionnaire 1, 17–18 7
Harris, 2007 [31] USA 229 285 NR 2002–2004 ASA/ NA-NSAIDs/
COX-2 inhibitors
Total PCa Interview 1, 6, 19–21 5
Menezes, 2006 [17] USA 1,029 1,029 67 1982–1998 ASA Total/advanced PCa Questionnaire 1, 6, 12 4
Mahmud, 2006 [30] Canada 494 805 64 1999–2003 ASA/ NSAIDs/ NA-NSAIDs/
COX-2 inhibitors
Total/advanced PCa Questionnaire 1, 12, 14, 15, 22–25 6
Liu, 2006 [29] USA 506 506 NR 2001–2004 ASA/ NSAIDs / NA-NSAIDs Advanced PCa Interview 1, 18, 26 5
Dasgupta, 2006 [28] Canada 2,025 2,150 73 1999–2002 ASA/ NA-NSAIDs Total PCa Database 1, 27 6
Bosetti, 2006 [16] Italy 1,261 1,131 65 1991–2002 ASA Total/advanced PCa Questionnaire 1, 7, 12, 28 5
Perron, 2003 [26] Canada 2,221 11,105 75.7 1993–1995 ASA/ NA-NSAIDs Total PCa Database 1, 29 6
Irani, 2002 [11] France 639 659 66.8 1999–2000 ASA/ NA-NSAIDs Total PCa Questionnaire 1, 14, 15, 18, 27, 30–32 6
Nelson, 2000 [23] USA 417 420 64.0 1992–1995 NA-NSAIDs/ NSAIDs Total PCa Interview 1, 18, 23 6
Langman, 2000 [35] UK 1,813 5,354 NR 1993–1995 NSAIDs Total PCa Database 1, 9 6
Norrish, 1998 [10] New Zealand 317 480 70.0 1996 ASA/ NSAIDs/ NA-NSAIDs Total/advanced PCa Questionnaire 1, 33–36 7
Neugut, 1998 [9] USA 319 189 69.0 1984–1986 ASA Total PCa Medical notes 1, 18, 13, 22 6




Shebl, 2012 [34] USA 3,573 29,450 62.8 11.7 ASA/NA-NSAIDs Total/advanced PCa Questionnaire 1, 12, 14, 15, 17, 18, 28 6
Dhillon, 2011 [20] USA 4,858 51,529 64.8 18.0 ASA Total/advanced PCa Questionnaire 1, 4, 6, 9, 12, 18, 20, 31,
36–39
8
Brasky, 2010 [19] USA 1,550 34,132 50–76 NR ASA/ NA-NSAIDs Total/advanced PCa Questionnaire
and Database
1, 6, 7, 12, 13, 18, 22,
39–45
5
Jacobs, 2007 [18] USA 1,076 69,810 NR 104,854
person-years
ASA Total PCa Questionnaire and
medical records
1, 6, 7, 9, 13, 15, 18, 20,
22, 45–47
7
Platz, 2005 [15] USA 141 1,244 70.0 9.0 ASA/NSAIDs/ NA-NSAIDs Total PCa Questionnaire 1, 14, 15, 23, 37, 7
Jacobs, 2005 [14] USA 4,853 70,144 NR 1992–2001 ASA/NSAIDs/ NA-NSAIDs Total/advanced PCa Questionnaire 1, 7, 12, 13, 18, 22, 45, 7


















Table 1 Characteristics of included studies: any NSAIDs use and PCa incidence risk (Continued)
Sorensen, 2003 [13] Denmark 324 172,057 NR 5.4 NA-NSAIDs Total PCa Database 1, 10, 11 7
Friis, 2003 [12] Denmark 196 29,470 70.0 4.1 ASA Total PCa Database 1, 10, 11 7
Roberts, 2002 [25] USA 91 1,362 64.0 5.5 NSAIDs Total PCa Questionnaire 1, 10, 12, 20 7
Habel, 2002 [24] USA 2,574 90,100 18–84 14.0 ASA Total/advanced PCa Questionnaire 1, 7, 17, 18, 6
Schreinemachers, 1994 [8] USA 123 12,668 65.0 12.4 ASA Total PCa Interview 1, 7, 9, 18, 21 5
Paganini-Hill, 1989 [7] USA 149 5106 73 6.5 ASA Total PCa Questionnaire 1 3
aaverage, median or range.Confounders for adjustment: 1, age; 2, benign prostatic hyperplasia medication use; 3, anti-diabetic medication; 4, cholesterol-lowering medication use; 5, antihypertensive medication use; 6,
body mass index; 7, school education; 8, deprivation; 9, smoking; 10, comorbidities; 11, use of medication; 12, family history of prostate cancer; 13, diabetes status; 14, aspirin use; 15, any NA-NSAID use; 16, ever visited
a urologist 1 to 11 years prior; 17, screened and volume of family physician visits; 18, race; 19, family history; 20, physical activity; 21, alcohol intake; 22, history of heart disease; 23, intake of acetaminophen; 24, reasons
for referral and prostate volume; 25, selective cyclooxygenase-2 (COX-2) inhibitors use; 26, medical institution; 27, finasteride use; 28, study center; 29, recent medical contacts; 30, farming; 31, frequency of red meat
and red wine consumption; 32, urological center; 33, socio-economic status; 34, total polyunsaturated fat consumption; 35, α-linolenic acid; 36, fatty acids; 37, period; 38, height; 39, vitamin; 40, osteoarthritis; 41,
rheumatoid arthritis; 42, chronic joint pain; 43, chronic headaches; 44, migraines; 45, PSA test in the past two years; 46, history of colorectal endoscopy; 47, hypertension; 48, prior benign prostate hyperplasia history.


















Table 2 Characteristics of included studies: any NSAIDs use and prostate cancer-specific mortality












Flahavan, 2014 [39] Ireland Cohort 2,936 104 70.5 5.5 Aspirin PR, RT, ADT I–III 1–8 8
Grytli, 2014 [40] Norway Cohort 3,561 1,010 76.3 3.3 Aspirin ADT I–IV 1, 2, 9–13 7
Cardwell, 2013 [41] UK Nested case–control 6,339 1,184 NR 6.0 Aspirin PR, RT, ADT, EST I–IV 1, 4, 8, 13–17 7
Dhillon, 2012 [42] USA Cohort 3,986 265 68.6 8.4 Aspirin/NSAIDs/
NA-NSAIDs
PR, RT, EST I–IIIab 1, 2, 4, 6, 10, 18–29 7
Choe, 2012 [43] USA Cohort 5,955 193 64.0 5.8 Aspirin RP, RT I–IV 1, 2, 9, 10, 29–31 8
Stock, 2008 [44] Canada Case–control 1,619 453 67.2 NR NSAIDs RP, RT I–IV 1, 2, 9, 21 7
Ratnasinghe, 2004 [45] USA Cohort NR 121 25–74 NR Aspirin NR NR 1, 4, 19, 21, 32–33 6
Lipworth, 2004 [46] Denmark Cohort NR 296 48.4 4.3 NA-NSAIDs NR NR 1, 33 5
Confounders for adjustment: 1, age; 2, tumor grade; 3, tumor size; 4, smoking status; 5, co-morbidity score; 6, year of incidence; 7, pre-diagnostic statin exposure 8, receipt of radiation; 9, prostate-specific antigen level;
10, Gleason score; 11, presence and type of metastases; 12, performance status; 13, androgen deprivation therapy initiated within six months after diagnosis; 14, year of cancer diagnosis; 15, chemotherapy within six
months of diagnosis; 16, estrogen therapy during exposure period; 17, comorbidities; 18, family history; 19, race; 20, height; 21, body mass index; 22, vigorous physical activity; 23, vitamin D; 24, fish; 25, red meat; 26,
cholesterol-lowering drugs; 27, total kcal; 28, aspirin use before diagnosis; 29, initial treatment; 30, aspirin use; 31, non-aspirin anticoagulant use; 32, poverty index; 33, education; 33, number of prescriptions. ADT,


















Favours NSAIDs Favours control
Figure 2 Association between use of any NSAIDs and incidence of prostate cancer.
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total cancer; OR = 0.99, 95% CI: 0.77 to 1.28 for advanced
cancer; OR = 1.00, 95% CI: (0.90 to 1.12 for non-advanced
cancer), both with substantial heterogeneity between stud-
ies except for non-advanced PCa analysis. Table 2 presents
the results of subgroup analyses.
For publication bias, the funnel plot was slightly asymmet-
ric (Figure 3C), and the P values for the Begg test and the
Egger test were 0.711 and 0.050, respectively, suggesting a
low probability of publication bias.
Association between any COX-2 inhibitor use and
PCa incidence
Five studies [21,30-32,37] evaluated COX-2 inhibitor use
and PCa risk. Overall, use of COX-2 inhibitors appeared
not to be statistically significantly associated with PCa risk
compared to non-use (Table 3; Additional file 5: Figure S3).
For studies with small numbers, we did not perform
subgroup analyses.
Association between any NSAID use and
PCa-specific mortality
Eight studies [39-46] investigated exposure to any NSAIDs
use (including aspirin use alone) with PCa-specific mor-
tality (Table 2). The pooled result shows that the use of
any NSAID had a neutral influence on the PCa-specific
mortality in a random effects model, with an HR = 1.00(95% CI: 0.68, 1.47) but with substantial heterogeneity
(I2 = 95.3%) (Table 3 and Additional file 5: Figure S4).
Studies of aspirin were more consistent; the pooled results
indicated that aspirin use was statistically significantly asso-
ciated with a modest reduction in PCa-specific mortality
(OR = 0.86, 95% CI: 0.78 to 0.96), with little evidence of het-
erogeneity (Table 3 and Figure 6). Confined to three studies
from North America, the HR was 0.85 (95% CI: 0.50 to 144)
but with more substantial heterogeneity (I2= 6%).
Discussion
This meta-analysis, involving a total of 108,136 PCa cases
from 39 observational studies, examined the association of
the use of any NSAID with the risk of PCa incidence or
mortality. The major finding of the present meta-analysis
provides support for the mechanistic hypothesis that aspirin
use (including long-term use of more than four years) is in-
versely related to the risk of PCa incidence. The association
was slightly stronger for advanced PCa than for total PCa
(OR = 0.92 for total PCa, OR = 0.81 for advanced PCa). A
cumulative meta-analysis showed that a statistically signifi-
cant effect of aspirin use on PCa incidence was consistently
observed after publication of the 13th trial in 2006. More
importantly, aspirin use demonstrated a 14% decrease
in PCa-specific mortality for total PCa compared to
non-use. In general, the pooled effects for any NSAIDs,
NA-NSAIDs and COX-2 inhibitors demonstrated no
Table 3 Results of subgroup analyses by outcome type and NSAIDs type
Study characteristics Number
of studies
OR (95% CI) PORvalue Effect model Heterogeneity
I2 (%) Pvalue
Risk of prostate cancer incidence
Any NSAIDs
Studies of total prostate cancer 11 0.90 (0.75, 1.07) 0.25 Random 93.5 <0.001
Case–control studies 8 0.97 (0.79, 1.20) 0.78 Random 93.8 <0.001
Cohort studies 3 0.71 (0.47, 1.07) 0.10 Random 81.4 0.005
Studies in North America 6 0.73 (0.60, 0.88) 0.001 Random 79.6 <0.001
Studies in Europe 5 1.29 (1.25, 1.34) <0.001 Fixed 37.2 0.17
Studies of advanced prostate cancer 5 0.86 (0.52, 1.40) 0.54 Random 94.2 <0.001
Aspirin
Studies of total prostate cancer 23 0.92 (0.87, 0.97) 0.002 Random 66.2 <0.001
Case–control studies 13 0.92 (0.85, 0.99) 0.040 Random 63.7 0.001
Cohort studies 10 0.91 (0.83, 0.99) 0.040 Random 71.7 <0.001
Studies from North America 16 0.92 (0.86, 0.97) 0.003 Random 53.7 0.006
Studies from Europe 7 0.94 (0.82, 1.08) 0.40 Random 80.7 <0.001
High quality studies 8 0.89 (0.81, 0.98) 0.022 Random 77.2 <0.001
Long-term aspirin use (≥4 years) 8 0.88 (0.79, 0.99) 0.038 Random 66.8 0.004
Studies of advanced prostate cancer 13 0.81 (0.73, 0.89) <0.001 Fixed 23.9 0.20
Case–control studies 7 0.84 (0.73, 0.98) 0.025 Fixed 23.7 0.18
Cohort studies 6 0.77 (0.67, 0.89) <0.001 Fixed 23.5 0.26
Studies from North America 9 0.82 (0.75, 0.89) <0.001 Fixed 14.0 0.32
Studies from Europe 4 0.88 (0.75, 1.03) 1.22 Fixed 48.2 0.12
High quality studies 6 0.81 (0.72, 0.92) 0.002 Fixed 38.1 0.152
Studies of non-advanced prostate cancer 6 0.96 (0.87, 1.07) 0.460 Fixed 33.6 0.177
Non-aspirin NSAIDs
Studies of total prostate cancer 17 1.01 (0.90, 1.13) 0.86 Random 90.1 <0.001
Case–control studies 11 0.97 (0.81, 1.17) 0.74 Random 93.0 <0.001
Cohort studies 6 1.07 (0.95, 1.20) 0.25 Random 69.6 0.006
Studies from North America 11 0.94 (0.85, 1.05) 0.28 Random 68.8 <0.001
Studies from Europe 6 1.18 (1.06, 1.32) 0.002 Random 71.1 0.004
Studies of advanced prostate cancer 9 0.99 (0.77, 1.28) 0.97 Random 81.6 <0.001
Studies of non-advanced prostate cancer 3 1.00 (0.90, 1.12) 0.943 Fixed 0.0 0.897
Any COX2 inhibitors
Studies of total prostate cancer 5 1.10 (0.90, 1.33) 0.36 Random 48.7 0.099
Studies of advanced prostate cancer 3 1.20 (0.79, 1.83) 0.40 Fixed 0.0 0.87
Risk of prostate cancer-specific mortality
Any NSAIDs (including aspirin use alone)
Studies of total prostate cancer 8 1.00 (0.68, 1.47) 0.99 Random 95.3 <0.001
Aspirin
Studies of total prostate cancer 6 0.86 (0.78, 0.96) 0.005 Fixed 39.2 0.15
Studies from North America 3 0.85 (0.50, 144) 0.55 Random 63.8 0.063
Studies from Europe 3 0.85 (0.76, 0.95) 0.005 Fixed 12.8 0.32
CI, confidence interval; COX-2, cyclooxygenase enzymes-2; OR, odds ratio.
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Figure 3 Funnel plots of the relative risk of total prostate
cancer incidence. (A) for any NSAIDs use; (B) for aspirin use; (C) for
non-aspirin NSAID use.
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http://www.biomedcentral.com/1741-7015/12/55adverse or beneficial effects on PCa development or PCa-
specific survival, but the results were not consistent; all
the effect estimates varied by geographic region.
There is a long-standing debate about the relationship
between NSAID use and cancer. Several reviewed studies
discussed the potential chemoprevention effects of NSAID
use against tumors at various sites, including breast [57],
lung [58] and brain [59], and melanoma [60]. This meta-
analysis, with a much larger number of participants than
previous meta-analyses [38,61], adds to the previous
findings by showing that aspirin use demonstrates a
protective effect against PCa. With a larger sample size,increased statistical power could be obtained. In addition,
we evaluated whether the association varied by COX-2 in-
hibitor, long-term aspirin use and study quality, and we in-
vestigated whether NSAID use influenced mortality from
the disease, issues that were not discussed in the primary
meta-analysis. Moreover, the present studies included
an approved quality evaluation system; thus, it was more
reliable in minimizing potential bias.
There are several proposed mechanisms by which these
effects could be explained. Primary laboratory studies have
pointed to COX-2 overexpression in PCa tissue [3], and it
is well established that increased expression of COX-2 is
related to tumor growth [4] and poorer prognosis [5].
NSAIDs inhibit PCa cell growth by reducing the synthesis
of prostaglandins by COX enzymes [62], including inducing
apoptosis [63], inhibiting cellular proliferation and angio-
genesis [64]. Animal and laboratory studies have confirmed
the preventive effect of NSAIDs on PCa repeatedly and con-
sistently. In a review of 12 studies, the authors reported that,
in all the included studies, all types of NSAIDs exhibited in-
hibitory effects on PCa development and progression.
In our study, use of aspirin was significantly inversely
related to the risks of developing advanced PCa but not
non-advanced PCa, which is difficult to explain. It may
possibly be explained by detection bias if aspirin users
were more likely to be screened and, therefore, to be
diagnosed at an earlier stage. However, this effect may
be real. Laboratory studies have suggested that advanced
stage PCa may represent heterogeneous etiologies [65] and
the mechanism by which aspirin acts on the initiation of
poorly-differentiated disease may be distinct from its influ-
ence on the development of advanced disease [20]. There
was also evidence that NSAIDs evoke tumor regression in
gastrointestinal tumors [66], and may have similar effects
against cancers of other sites including the prostate. Our
findings with regard to the effects of aspirin on disease se-
verity require confirmation in larger studies using unbiased
diagnostic approaches.
We postulated that the use of aspirin reduced overall
PCa risk. This could have significant implications with
respect to the dose, frequency and duration of aspirin
use. Unfortunately, most studies lacked information on dos-
age, frequency and duration of exposure. Although some
studies have provided this information, they varied in each
trial, resulting in invalid statistical analysis in these groups.
In a study by Veitonmaki et al. [37] in 2013, a dose–effect
relationship was found, indicating a significant inverse asso-
ciation (OR = 0.83) only among participants who used as-
pirin at the dosage of 37 to 1,300 defined daily dose (DDD).
The other benefit was shown among those who took more
than one aspirin pill per day [23,29,34], a low dose (≤75 mg/
daily) [27,32], larger doses (≥325 mg/daily) [26] or more
than six tablets/week [20]; nevertheless, other studies
found no evidence of a dose–effect [7,10,17,19,33,35]
Figure 4 Association between aspirin use and incidence of prostate cancer.
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http://www.biomedcentral.com/1741-7015/12/55or frequency–effect [14,16,17] relationship. In terms of
the duration of aspirin use, we used the available data
from eight studies [15,17-20,26,27,32] with durations of
more than four years. Our pooled results demonstrated
a negative trend of PCa risk with more than four years
of aspirin use.
Considering the high incidence of PCa and the wide-
spread use of aspirin in the general population, there-
fore, successful prevention could have a major public
health impact. However, physicians should be aware of
which subgroups of the population are at high risk for
PCa, and the optimal dosage of aspirin, as well as its
side effects, should be addressed. It seems that the use
of aspirin in clinical prevention still has a long way to
go, but, at least, the evidence implies that it is benefi-
cial against the risk of PCa.
Nevertheless, several limitations of this study must be
acknowledged. First, heterogeneity was a potential problem
when interpreting the results of our analysis. In our meta-
analysis, significant heterogeneity was observed in many of
the analyses we conducted. Despite stratifying the data intosubgroups based on type of outcome, study design,
geographic region, quality of study and duration of as-
pirin use, some heterogeneity was still detected. In fact,
it is no surprise given the differences of each study in the
definition of drug exposure, information collection methods
(for example, questionnaires or medical records), race, age
and lifestyle factors of participants, sample size, duration of
study follow-up and so on.
Second, as shown in Table 1 and Table 2, the number
and content of the adjusted confounders differed among
studies, which could have caused some imprecision in the
effect estimates. The established risk factors for PCa are
African-American ethnicity and family history of PCa [65].
Most studies adjusted for age and race using multivariate
statistical models. Few studies adjusted for family history of
PCa. However, researchers do not always make the same
decisions concerning confounding factors. We did our best
to minimize these confounding biases by choosing the most
multivariable adjusted-effect estimates to analyze.
In addition, several sources of bias could have affected
our observed associations. First, observational studies have
Favours non-aspirin NSAIDs Favours control
Figure 5 Association between non-aspirin NSAID use and incidence of prostate cancer.
Figure 6 Association between aspirin use and prostate cancer-specific mortality.
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founding. On the other hand, screening and surveillance
biases are potentially a major source of systemic error in
the reviewed studies. NSAID use may be associated with
the socioeconomic status of patients. Thus, NSAID users
might maintain healthier lifestyle habits than non-users,
which could influence their risk for PCa. Moreover,
NSAID users may have easier and more frequent access to
preventive healthcare services, such as screening for
prostate-specific antigen (PSA), which theoretically could
lower the incidence of PCa.
At this stage, randomized controlled trials (RCTs) would
be required to evaluate further the relationship between
NSAIDs and PCa risk. However, RCTs for this topic could
be extremely difficult or even impossible. First, PCa is rare
and mainly occurs in older men; second, too many people
in the general population take NSAIDs, especially as-
pirin, for various important medical reasons. This will
render randomization and adherence to the protocol
impossible. If one wants to conduct such a trial in younger
subjects who do not take NSAIDS, investigators will run
into the trouble of having enough end-points (events) given
their young age.
Conclusions
Our current study, based on the available studies and
updated data from a previous meta-analysis, supports the
hypothesis that aspirin use (including long-term use) pro-
vides potential benefits in the reduction of PCa incidence
and PCa-specific mortality. The inverse association was
slightly stronger for advanced PCa than for total PCa, but
the effect estimates varied by geographic region. Also un-
clear is the influence of dose and the frequency of aspirin
use on PCa incidence and outcomes. Thus, caution needs
to be exercised to ensure that the associated prevention
benefits of aspirin outweigh the potential side effects
(for example. gastrointestinal bleeding).
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